<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJOph</journal-id><journal-title-group><journal-title>Open Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2165-7408</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojoph.2014.43012</article-id><article-id pub-id-type="publisher-id">OJOph-48252</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>MEDICINE &amp; HEALTHCARE</subject></subj-group></article-categories><title-group><article-title>Meta-Herpetic Keratitis and Therapeutic Approach: Case Report</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ozlem</surname><given-names>Sahin</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Ophthalmology/Uveitis, DunyaGoz Hospital Ltd., Ankara, Turkey</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>ozlem1158@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>07</month><year>2014</year></pub-date><volume>04</volume><issue>03</issue><fpage>75</fpage><lpage>78</lpage><history><date date-type="received"><day>27</day>	<month>May</month>	<year>2014</year></date><date date-type="rev-recd"><day>30</day>	<month>June</month>	<year>2014</year>	</date><date date-type="accepted"><day>23</day>	<month>July</month>	<year>2014</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
	The purpose of this
study is to disclose the steps in the therapeutic approach for meta-herpetic corneal
ulcer. Report of a case with anterior segment photography was used. The 6
months of follow-up results of the case were disclosed. The efficacy of the therapeutic approach for meta-herpetic corneal ulcer was discussed. 
</p></abstract><kwd-group><kwd>Corneal Ulcer</kwd><kwd> Corneal Neovascularization</kwd><kwd> Herpes Simplex Virus-1</kwd><kwd> Meta-Herpetic Keratitis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Herpes simplex virus type 1 (HSV-1) is regarded as a common cause of keratitis [<xref ref-type="bibr" rid="scirp.48252-ref1">1</xref>] . The clinical types of keratitis caused by HSV-1 is classified as epithelial keratitis, (dendritica, geographica) stromal keratitis, (necrotizing, non-necrotizing) endotheliitis, (disciform keratitis) meta-herpetic keratitis, (neurotrophic keratopathy) and vascularized corneal scars [<xref ref-type="bibr" rid="scirp.48252-ref1">1</xref>] . Meta-herpetic corneal disease is considered as a chronic or chronic recurrent superficial post-herpetic corneal inflammation without any detectable HSV-1-activity [<xref ref-type="bibr" rid="scirp.48252-ref2">2</xref>] . Meta-herpetic erosion, ulcer and bullous keratopathy are the main types of meta-herpetic corneal disease [<xref ref-type="bibr" rid="scirp.48252-ref2">2</xref>] . Metaherpetic corneal inflammation is widely considered a therapeutic challenge. The purpose of this study is to disclose the steps in the therapeutic approach for meta-herpetic corneal ulcer.</p></sec><sec id="s2"><title>2. Case Report</title><p>75-year-old male admitted with the symptoms of redness, tearing, photophobia and blurred vision in the right eye. He had a history of right recurrent HSV-1 epithelial keratitis in the last 2 years. He had been treated with only topical antiviral medications. The last episode of HSV-1 epithelial keratitis was 6 months ago. Best corrected visual acuities (BCVA) on admission were 20/400 in the right eye and 20/20 in the left eye. The intraocular pressures were 10 and 8 mm Hg respectively. Biomicroscopic examination of the right eye disclosed a centrally locateddeep corneal ulcer with smooth edges associated with stromal inflammation, descemet’s folds and 270 degrees of peripheral corneal neovascularization 1 - 5 mm from the limbus (<xref ref-type="fig" rid="fig1">Figure 1</xref>). He had a posterior chamber intraocular lens. (PCIOL) Biomicroscopic examination of the left eye disclosed a PCIOL and fundus examination of both eyes were normal. The corneal scraping specimens for bacterial and fungal cultures were negative. He was diagnosed as meta-herpetic corneal ulcer in theright eye. Treatment with valacyclovir 1000 mg twice a day, fibronectin drops prepared from the patient’s serum, sustained release doxycycline, vitamin C, loteprednol etabonate (LE) associated with frequent use of preservative free artificial tears were initiated. Biomicroscopic examination at the 3<sup>rd</sup> week of follow-up revealed the healing of corneal ulcer, decrease stromal inflammation with the resolution of descemet’s folds and diminished peripheral corneal neovascularization (<xref ref-type="fig" rid="fig2">Figure 2</xref>). He received the same treatment with decreasing doses of LE for 6 months. His examination at the 6<sup>th</sup> month of treatment revealed an increase in BCVA of the right eye to 20/40. Right cornea disclosed a central deep stromal scar without inflammation and neovascularization associated with sub-epithelial irregularities (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><fig id="fig1"><label>Figure 1</label><caption><p> Anterior segment photo of the right cornea. Note centrally located deep corneal ulcer with smooth edges associated with stromal inflammation, descemet’s folds and peripheral corneal neovascularization</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\3-2020099x\0eb0d41b-720b-4764-8929-f4b01e5d97df.png"/></fig><fig id="fig2"><label>Figure 2</label><caption><p> Anterior segment photo of the right cornea in the 3<sup>rd</sup> week of follow-up. Note healing of the corneal ulcer, decreased stromal inflammation with the resolution of descemet’s folds and diminished peripheral corneal neovascularization</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\3-2020099x\0ee55af3-4674-4139-bd2d-4a278ed46391.png"/></fig><fig id="fig3"><label>Figure 3</label><caption><p> Anterior segment photo of the right cornea at the 6<sup>th</sup> month of follow-up. Note a central deep stromal scar without inflammation and corneal neovascularization associated with sub-epithelial irregularities</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\3-2020099x\a783480a-87c2-46a7-a943-8d8c293c549d.png"/></fig></sec><sec id="s3"><title>3. Discussion</title><p>Meta-herpetic keratitis is described as a structural damage by the immune and inflammatory mechanisms in the aftermath of HSV-1 corneal infection [<xref ref-type="bibr" rid="scirp.48252-ref3">3</xref>] . The rupture of the Bowman’s membrane with collagenases is shown to make the deep corneal ulcer possible [<xref ref-type="bibr" rid="scirp.48252-ref4">4</xref>] . Diagnosis of meta-herpetic keratitis is primarily based on a prior history of HSV-1 keratitis [<xref ref-type="bibr" rid="scirp.48252-ref5">5</xref>] . Serological investigations are not usually necessary [<xref ref-type="bibr" rid="scirp.48252-ref5">5</xref>] . This case had a history of recurrent epithelial keratitis treated with only topical antiviral medications. However, oral acyclovir has been recommended for the treatment of recalcitrant epithelial, stromal or uveal diseases secondary to HSV-1 [<xref ref-type="bibr" rid="scirp.48252-ref6">6</xref>] . The patient received inadequate treatment for recurrent HSV-1 keratitis. Diagnosis of meta-herpetic keratitis in this case was made on the basis of his prior history, biomicroscopic findings of deep ulcer with smooth edges associated with stromal inflammation, peripheral corneal neovascularization, and no growth of bacteria or fungi from the corneal scraping specimens. Treatment of meta-herpetic keratitis is challenging. Topical steroids are generally contraindicated in the presence of HSV epithelial keratitis [<xref ref-type="bibr" rid="scirp.48252-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.48252-ref6">6</xref>] . However, judicious topical steroid therapy is considered beneficial when combined with protective anti-viral coverage [<xref ref-type="bibr" rid="scirp.48252-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.48252-ref6">6</xref>] . The patient was treated with LE 0.5% five times a day. LE was shown to be highly lipophilic, and the highest concentrations of LE were reported to be found in the cornea followed by the iris, ciliary body and the aqueous humor [<xref ref-type="bibr" rid="scirp.48252-ref7">7</xref>] . Previous studies related to comparison of oral anti-viral therapy with valacyclovir or acyclovir revealed similar anti-viral potencies with less frequent dosages of valacyclovir [<xref ref-type="bibr" rid="scirp.48252-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.48252-ref9">9</xref>] . Valacyclovir 500 - 1000 mg twice a day is found as effective as acyclovir 200 mg five times a Day [<xref ref-type="bibr" rid="scirp.48252-ref9">9</xref>] . Valacyclovir has been recommended for the patients having difficulty in complying with the acyclovir doses [<xref ref-type="bibr" rid="scirp.48252-ref10">10</xref>] . The patient received valacyclovir 1000 mg twice a day with clinical improvement in 6 months. The efficacy of fibronectin eye drops which are prepared from patients own blood plasma has been shown for the non-healing corneal epithelial defects after HSV-1 keratitis [<xref ref-type="bibr" rid="scirp.48252-ref11">11</xref>] . This case was treated with fibronectin eye drops for the deep seated central corneal ulcer. The expression of matrix metalloproteinase (MMPs) by resident corneal cells or by inflammatory cells has been disclosed in experimental HSV-1 keratitis [<xref ref-type="bibr" rid="scirp.48252-ref12">12</xref>] . MMPs have been considered to promote epithelial keratitis, ulcerative process and stromal liquefaction after corneal HSV-1 infection [<xref ref-type="bibr" rid="scirp.48252-ref12">12</xref>] . Combining antiviral therapy with MMPs inhibitors has been revealed to speed corneal healing [<xref ref-type="bibr" rid="scirp.48252-ref13">13</xref>] . MMPs inhibitors are considered to inhibit corneal neovascularization by inhibiting the expression of vascular endothelial growth factor and the interleukin-1β [<xref ref-type="bibr" rid="scirp.48252-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.48252-ref15">15</xref>] . This case received sustained release doxycycline for 6 months. The deep central corneal ulcer and peripheral corneal neovascularization were resolved with this treatment at the end of 6<sup>th</sup> month. Topical or systemic administrations of vitamin C or ascorbic acid have been shown to reduce corneal stromal inflammation through inhibition of polymorphonuclear leukocytes by the previous studies [<xref ref-type="bibr" rid="scirp.48252-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.48252-ref17">17</xref>] . The patient was treated with vitamin C orally for 6 months to promote the healing of the corneal ulcer. In conclusion; meta-herpetic keratitis is difficult to treat. We recommend early onset of systemic antiviral therapy in conjunction with smart use of topical steroids, MMPs inhibitors, vitamin C, fibronectin eye drops and preservative free lubricants.</p></sec><sec id="s4"><title>Funding</title><p>Author does not have grants or funds in support of the study.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.48252-ref1"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SEITZ</surname><given-names> B. </given-names></name>,<name name-style="western"><surname> HEILIGENHAUS</surname><given-names> A. </given-names></name>,<etal>et al</etal>. (<year>2011</year>)<article-title>HERPETIC KERATITIS. VARIOUS EXPRESSIONS REQUIRE DIFFERENT THERAPEUTIC APPROACHES</article-title><source> OPHTHALMOLOGE</source><volume> 108</volume>,<fpage> 385</fpage>-<lpage>395</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1007/S00347-011-2346-5</pub-id></mixed-citation></ref><ref id="scirp.48252-ref2"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SUNDMACHER</surname><given-names> R. </given-names></name>,<name name-style="western"><surname> NEUMANN-HAEFELIN</surname><given-names> D. </given-names></name>,<etal>et al</etal>. (<year>1976</year>)<article-title>SUNDMACHER, R. AND NEUMANN-HAEFELIN, D.  META-HERPETIC KERATITIS CLINICAL AND VIROLOGICAL FINDINGS</article-title><source> KLIN MONBL AUGENHEILKD</source><volume> 169</volume>,<fpage> 728</fpage>-<lpage>737</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.48252-ref3"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>LIESEGANG</surname><given-names> T.J. </given-names></name>,<etal>et al</etal>. (<year>1999</year>)<article-title>CLASSIFICATION OF HERPES SIMPLEX VIRUS KERATITIS AND ANTERIOR UVEITIS</article-title><source> CORNEA</source><volume> 18</volume>,<fpage> 127</fpage>-<lpage>143</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1097/00003226-199903000-00001</pub-id></mixed-citation></ref><ref id="scirp.48252-ref4"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>ALGAN</surname><given-names> B. </given-names></name>,<etal>et al</etal>. (<year>1978</year>)<article-title>CONSIDERATIONS ON THE META-HERPETIC KERATITIS</article-title><source> KLIN MONBL AUGENHEILKD</source><volume> 172</volume>,<fpage> 609</fpage>-<lpage>616</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.48252-ref5"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>WILHELMUS</surname><given-names> K.R. </given-names></name>,<etal>et al</etal>. (<year>1987</year>)<article-title>DIAGNOSIS AND MANAGEMENT OF HERPES SIMPLEX STROMAL KERATITIS</article-title><source> CORNEA</source><volume> 6</volume>,<fpage> 286</fpage>-<lpage>291</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1097/00003226-198706040-00011</pub-id></mixed-citation></ref><ref id="scirp.48252-ref6"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SCHWAB</surname><given-names> I.R. </given-names></name>,<etal>et al</etal>. (<year>1988</year>)<article-title>ORAL ACYCLOVIR IN THE MANAGEMENT OF HERPES SIMPLEX OCULAR INFECTIONS</article-title><source> OPHTHALMOLOGY</source><volume> 95</volume>,<fpage> 423</fpage>-<lpage>430</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/S0161-6420(88)33156-8</pub-id></mixed-citation></ref><ref id="scirp.48252-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">COMSTOCK, T.L. AND DECORY, H.H. (2012) ADVANCES IN CORTICOSTEROID THERAPY FOR OCULAR INFLAMMATION: LOTEPREDNOL ETABONATE. INTERNATIONAL JOURNAL OF INFLAMMATION, 2012, ARTICLE ID: 789623.</mixed-citation></ref><ref id="scirp.48252-ref8"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>GOLDBLUM</surname><given-names> D.</given-names></name>,<name name-style="western"><surname> BACHMANN</surname><given-names> C.</given-names></name>,<name name-style="western"><surname> TAPPEINER</surname><given-names> C.</given-names></name>,<name name-style="western"><surname> ET AL. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2008</year>)<article-title>COMPARISON OF ORAL ANTIVIRAL THERAPY WITH VALACYCLOVIR OR ACYCLOVIR AFTER PENETRATING KERATOPLASTY FOR HERPETIC KERATITIS</article-title><source> BRITISH JOURNAL OF OPHTHALMOLOGY</source><volume> 92</volume>,<fpage> 1201</fpage>-<lpage>1205</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1136/BJO.2008.138065</pub-id></mixed-citation></ref><ref id="scirp.48252-ref9"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>PERRY</surname><given-names> C.M. </given-names></name>,<name name-style="western"><surname> FAULDS</surname><given-names> D. </given-names></name>,<etal>et al</etal>. (<year>1996</year>)<article-title>VALACYCLOVIR: A REVIEW OF ITS ANTIVIRAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN HERPES VIRUS INFECTIONS</article-title><source> DRUGS</source><volume> 52</volume>,<fpage> 754</fpage>-<lpage>772</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.2165/00003495-199652050-00009</pub-id></mixed-citation></ref><ref id="scirp.48252-ref10"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SHIMOMURA</surname><given-names> Y. </given-names></name>,<etal>et al</etal>. (<year>2008</year>)<article-title>1 HERPES SIMPLEX VIRUS LATENCY, REACTIVATION AND A NEW ANTIVIRAL THERAPY FOR HERPETIC KERATITIS</article-title><source> NIHON GANKA GAKKAI ZASSHI</source><volume> 12</volume>,<fpage> 247</fpage>-<lpage>264</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.48252-ref11"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>NISHIDA</surname><given-names> T.</given-names></name>,<name name-style="western"><surname> NAKAGAWA</surname><given-names> S. </given-names></name>,<name name-style="western"><surname> MANABE</surname><given-names> R. </given-names></name>,<etal>et al</etal>. (<year>1985</year>)<article-title>CLINICAL EVALUATION OF FIBRONECTIN EYE DROPS ON EPITHELIAL DISORDERS AFTER HERPETIC KERATITIS</article-title><source> OPHTHALMOLOGY</source><volume> 92</volume>,<fpage> 213</fpage>-<lpage>216</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/S0161-6420(85)34050-2</pub-id></mixed-citation></ref><ref id="scirp.48252-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">YANG, Y.N., BAUER, D., LI, H.P., ET AL. (2004) EXPRESSION OF MATRIX METALLOPROTEINASES IN EXPERIMENTAL HERPES SIMPLEX VIRUS KERATITIS. ZHONGHUA YAN KE ZA ZHI, 40, 395-399.</mixed-citation></ref><ref id="scirp.48252-ref13"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>BROOKS</surname><given-names> D.E. </given-names></name>,<name name-style="western"><surname> OLLIVIER</surname><given-names> F.J. </given-names></name>,<etal>et al</etal>. (<year>2004</year>)<article-title>MATRIX METALLOPROTEINASE INHIBITION IN CORNEAL ULCERATION</article-title><source> VETERINARY CLINICS OF NORTH AMERICA: SMALL ANIMAL PRACTICE</source><volume> 34</volume>,<fpage> 611</fpage>-<lpage>622</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/J.CVSM.2003.12.005</pub-id></mixed-citation></ref><ref id="scirp.48252-ref14"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>PEYMAN</surname><given-names> G.A.</given-names></name>,<name name-style="western"><surname> KAZI</surname><given-names> A.A.</given-names></name>,<name name-style="western"><surname> RIAZI-ESTAFANI</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> ET AL. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2006</year>)<article-title>THE EFFECT OF COMBINATIONS OF FLURBIPROFEN, LOW MOLECULAR WEIGHT HEPARIN AND DOXYCYCLINE ON THE INHIBITION OF CORNEAL NEOVASCULARIZATION</article-title><source> CORNEA</source><volume> 25</volume>,<fpage> 582</fpage>-<lpage>585</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1097/01.ICO.0000220767.73660.3A</pub-id></mixed-citation></ref><ref id="scirp.48252-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">LING, S., LI, W., LIU, L., ET AL. (2013) ALLOGRAFT SURVIVAL ENHANCEMENT USING DOXYCYCLINE IN ALKALI-BURNED MOUSE CORNEA. ACTA OPHTHALMOLOGICA, 91, 369-378.</mixed-citation></ref><ref id="scirp.48252-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">GUNBY, P. (1980) VITAMIN C MAY ENHANCE HEALING OF CAUSTIC CORNEAL BURNS. JAMA, 243, 623. HTTP://DX.DOI.ORG/10.1001/JAMA.1980.03300330003001</mixed-citation></ref><ref id="scirp.48252-ref17"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>PFISTER</surname><given-names> R.P. </given-names></name>,<name name-style="western"><surname> PATERSON</surname><given-names> C.A. </given-names></name>,<etal>et al</etal>. (<year>1980</year>)<article-title>ASCORBIC ACID IN THE TREATMENT OF ALKALI BURNS OF THE EYE</article-title><source> OPHTHALMOLOGY</source><volume> 87</volume>,<fpage> 1050</fpage>-<lpage>1057</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1016/S0161-6420(80)35126-9</pub-id></mixed-citation></ref></ref-list></back></article>